Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD-Reference-Cited by-同舟云学术

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD

Published:2016-01-12 Issue:6 Volume:99 Page:642-650
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Brown JT¹,Abdel-Rahman SM²,van Haandel L²,Gaedigk A²,Lin YS³,Leeder JS²

Affiliation:

1. Department of Pharmacy Practice and Pharmaceutical Sciences; University of Minnesota College of Pharmacy; Duluth Minnesota USA

2. Division of Clinical Pharmacology; Toxicology, and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City and University of Missouri-Kansas City; Kansas City Missouri USA

3. Department of Pharmaceutics; University of Washington School of Pharmacy; Seattle Washington USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.319/fullpdf

Reference26 articles.

1. Identification of the human cytochromes P450 responsible for atomoxetine metabolism;Ring;Drug Metab. Dispos.,2002

2. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism;Sauer;Drug Metab. Dispos.,2003

3. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder;Witcher;J. Child Adolesc. Psychopharmacol.,2003

4. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD;Michelson;J. Am. Acad. Child Adolesc. Psychiatry,2007

5. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype;Gaedigk;Clin. Pharmacol. Ther.,2008

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of SLC6A2 and CYP2D6 polymorphisms’ effects on atomoxetine treatment in attention deficit and hyperactivity disorder;European Journal of Clinical Pharmacology;2024-08-19

2. Evaluation of SLCA62 and CYP2D6 Polymorphisms’ Effects on Atomoxetine Treatment in Attention Deficit and Hyperactivity Disorder;2024-05-30

3. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together;Translational Psychiatry;2024-03-19

4. Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit/Hyperactivity Disorder;Clinical Pharmacology & Therapeutics;2024-01-08

5. Pharmacokinetic Models Scaled Up from Humanized Liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated andN-Demethylated Metabolites in Pediatric Patients Genotyped for CytochromeP450 2D6;Drug Metabolism and Disposition;2023-10-25